PremiumIntas Pharmaceuticals Ltd is preparing a bid for Biogen Inc.’s biosimilar business in a transaction that could be valued at as much as $1 billion, two people familiar with the talks said.

两位熟悉会谈的人表示，PremiumIntas制药有限公司正在为Biogen Inc.的生物仿制药业务准备一项价值高达10亿美元的交易。

Ahmedabad-based Intas is being advised by Goldman Sachs Group Inc., one of the people said, adding that the company ......This is a Premium article. Please subscribe or log in to read the full story!Here's a selection of our recent premium content.Become a Premium memberAlready a member? Click here to log in..

其中一位人士说，高盛萨克斯集团公司正在为基于艾哈迈达巴德的Intas提供建议，并补充说，该公司。。。。。。这是一篇优质文章。请订阅或登录阅读完整故事！这是我们最近的优质内容的选择。成为高级会员已经成为会员？点击这里登录。。